Author:
Maines Francesca,Caffo Orazio,Veccia Antonello,Trentin Chiara,Tortora Giampaolo,Galligioni Enzo,Bria Emilio
Funder
Italian Association for Cancer Research (AIRC)
Italian Ministry of Education, Universities and Research
Reference38 articles.
1. Cabazitaxel remains active in patients progressing after docetaxel followed by novel and rogen receptor pathway targeted therapies;Al Nakouzi;Eur. Urol.,2014
2. Response to cabazitaxel in the postchemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate;Albiges;Ann. Oncol.,2012
3. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer;Antonarakis;N. Engl. J. Med.,2014
4. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naïve metastatic castration-resistant prostate cancer patients;Azad;Eur. Urol.,2014
5. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment;Badrising;Cancer,2014
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献